We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Industry Requests CMS Delay Implementation of AMP Final Rule

Industry Requests CMS Delay Implementation of AMP Final Rule

September 19, 2007

PhRMA, the Biotechnology Industry Organization and the Generic Pharmaceutical Association sent a letter Sept. 18 to Kerry Weems, acting administrator of the Centers for Medicare & Medicaid Services (CMS), requesting that the agency delay implementation of its final rule on Medicaid average manufacturer price (AMP) reporting.

“This delay is essential to allowing the time needed to accomplish the large-scale systems changes and validation needed to support accurate data reporting and to avoid significant program disruptions,” the trade groups wrote.

When the CMS published the rule earlier this year, it established an Oct. 1 implementation date. It also set a six-month comment period for two aspects of the rule: the definition of AMP and the elimination of any drug from the AMP calculation priced significantly lower than other drugs in their category.

The trade groups are asking CMS to delay the implementation date until the quarter following the end of the comment period, Jan. 2, 2008.

Compliance with the rule requires extensive changes in reporting systems and algorithms, and the deadline does not allow sufficient time to validate system changes, the groups said, potentially leading to unreliable and noncompliant data being submitted to the agency.

Use of such data could lead to repeated errors and corrections, creating confusion and inappropriately exposing stakeholders to liabilities, the groups said. In addition, reporting unreliable data to the agency may compromise the integrity of the Medicaid program, considering AMPs will be published.

The CMS did not respond to a request for comment by press time.

    Upcoming Events

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Mold, Contaminated Containers Steer FDA to Untitled Letter for Novartis’ Kymriah

    • Recall of Cordis Angiographic Catheter for Lack of Sterilization Deemed Class I

    • AbbVie to Buy Cerevel Therapeutics for $8.7 Billion

    • Medtronic Terminates $738 Million EOFlow Deal

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing